草酸艾司西酞普兰治疗中度阿尔茨海默病患者精神行为症状、认知障碍和安全性研究

Study on the Safety of Escitalopram Oxalate in the Treatment of Psycho-behavioral Symptoms,Cognitive Impairment and Safety in Patients with Moderate Alzheimer's Disease

目的探究在阿尔茨海默病患者的治疗中采用西酞普兰治疗对于患者精神行为症状、认知障碍改善情况和安全性情况。方法选取该院2018年1月—2020年1月收治的100例中度阿尔茨海默病患者作为该次研究对象,基于使用药物的区别分为西酞普兰组与安慰剂组,每组50例。西酞普兰组采用口服西酞普兰进行治疗,安慰剂组采用等剂量的安慰剂进行治疗,除此之外,两组患者均进行盐酸美金刚片口服治疗,连续治疗90d后对比两组患者的MMSE评分、NPI改善情况与不良反应情况。结果两组患者治疗结束后,MMSE评分均有所增加,西酞普兰组增加的分值为(0.69±0.78)分明显高于安慰剂组评分(0.26±0.67)分,组间差异有统计学意义(t=2.957,P<0.05);而在NPI改善情况方面,西酞普兰组相对于安慰剂组而言,其攻击性(2.77±1.22)分,(2.03±0.96)分、抑郁情况(1.19±0.92)分,(0.13±0.41)分、焦虑情况(1.33±1.18)分,(0.08±0.27)分、情感感受情况(0.62±0.88)分,(0.13±0.41)分均明显降低,组间差异有统计学意义(t=3.371、7.441、7.301、3.568,P<0.05);而在不良反应方面,两组患者出现头晕、头痛、恶心、乏力等不良反应例数比较,差异无统计学意义(t=0.457,P>0.05)。结论在中度阿尔茨海默病且伴有一定精神行为症状患者的治疗中,采用西酞普兰配合盐酸美金刚片进行口服治疗能够有效的改善患者的精神行为状态,改善患者的认知障碍情况,且不会增加患者的不良反应情况,是一种安全可靠的药物。

Objective To explore the effect of citalopram treatment in the treatment of patients with Alzheimer's disease on the improvement of mental and behavioral symptoms,cognitive impairment and safety of patients.Methods A total of 100 patients with moderate Alzheimer's disease admitted to the hospital from January 2018 to January 2020 were selected as the subjects of this study.Based on the difference in the use of drugs,they were divided into citalopram group and placebo group,with 50 cases in each group.The citalopram group was treated with oral citalopram,and the placebo group was treated with an equal dose of placebo.In addition,the two groups of patients were treated with memantine hydrochloride tablets orally.After 90 days of continuous treatment,the two groups were compared.MMSE score,NPI improvement and adverse reactions.Results After the treatment of the two groups,the MMSE scores increased.The score of the citalopram group was(0.69±0.78)points significantly higher than the score of the placebo group(0.26±0.67)points,and the difference between the groups was statistically significant(t=2.117,P<0.05).In terms of NPI improvement,compared with the placebo group,the citalopram group had aggressive(2.77±1.22)points,(2.03±0.96)points,and depression(1.19±0.92)points,(0.13±0.41)points,anxiety(1.33±1.18)points,(0.08±0.27)points,emotional feelings(0.62±0.88)points,(0.13±0.41)points were significantly reduced,between groups the difference was statistically significant(t=3.371,7.441,7.301,3.568,P<0.05);in terms of adverse reactions,there was not statistically significant difference the number of adverse reactions such as dizziness,headache,nausea,and fatigue between the two groups(t=0.457,P>0.05).Conclusion In the treatment of patients with moderate Alzheimer’s disease and certain mental and behavioral symptoms,the oral treatment of citalopram combined with memantine hydrochloride tablets can effectively improve the mental and behavioral state of the patients and improve the patient’s mental and behavioral status.It is a safe and reliable medicine for cognitive impairment without increasing the adverse reactions of patients.